Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Corbus Pharmaceuticals Hldgs Inc (CRBP)

Corbus Pharmaceuticals Hldgs Inc (CRBP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 180,552
  • Shares Outstanding, K 17,736
  • Annual Sales, $ 0 K
  • Annual Income, $ -78,540 K
  • EBIT $ -85 M
  • EBITDA $ -86 M
  • 60-Month Beta 2.78
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.17

Options Overview Details

View History
  • Implied Volatility 83.04% (-20.85%)
  • Historical Volatility 85.55%
  • IV Percentile 2%
  • IV Rank 3.15%
  • IV High 489.47% on 02/20/26
  • IV Low 69.83% on 05/22/25
  • Expected Move (DTE 3) 0.55 (5.51%)
  • Put/Call Vol Ratio 0.24
  • Today's Volume 1,249
  • Volume Avg (30-Day) 739
  • Put/Call OI Ratio 0.19
  • Today's Open Interest 16,034
  • Open Int (30-Day) 13,184
  • Expected Range 9.47 to 10.57

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-1.26
  • Number of Estimates 5
  • High Estimate $-1.11
  • Low Estimate $-1.37
  • Prior Year $-1.39
  • Growth Rate Est. (year over year) +9.35%

Price Performance

See More
Period Period Low Period High Performance
1-Month
8.10 +23.70%
on 03/25/26
10.73 -6.62%
on 04/09/26
+0.61 (+6.48%)
since 03/13/26
3-Month
7.20 +39.17%
on 02/19/26
10.73 -6.62%
on 04/09/26
+1.76 (+21.31%)
since 01/14/26
52-Week
5.73 +74.87%
on 04/15/25
20.56 -51.26%
on 10/20/25
+4.22 (+72.76%)
since 04/14/25

Most Recent Stories

More News
Corbus Pharmaceuticals Announces Last Patient First Visit in CANYON-1 Study of CRB-913 for the Treatment for Obesity

On track to complete 16-week, dose-finding Phase 1b study (n=240) in summer 2026 Phase 1b data will build upon Phase 1a findings that demonstrated weight loss of nearly 3% at 14 days in individuals...

CRBP : 10.02 (-1.57%)
Corbus Pharmaceuticals Announces Broad Alignment with FDA on Registration Path for CRB-701 in Second-Line HNSCC and Cervical Cancer

FDA feedback enables Corbus to proceed with proposed registrational study design and endpoints to support potential accelerated approval in second-line HNSCC and cervical cancer Updated CRB-701 monotherapy...

CRBP : 10.02 (-1.57%)
Corbus Pharmaceuticals to Participate in the BMO 2026 Metabolic Health Summit

NORWOOD, Mass., March 18, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), a clinical-stage company focused promising new therapies in oncology and obesity, today announced...

CRBP : 10.02 (-1.57%)
Corbus Pharmaceuticals: Q4 Earnings Snapshot

Corbus Pharmaceuticals: Q4 Earnings Snapshot

CRBP : 10.02 (-1.57%)
Corbus Pharmaceuticals Reports Q4 and 2025 Financial Results and Provides a Corporate Update

Presented data at ESMO 2025 demonstrating promising efficacy with CRB-701 in head and neck squamous cell carcinoma (HNSCC) and cervical cancer CRB-701 data for both indications is expected in mid-2026...

CRBP : 10.02 (-1.57%)
Corbus Pharmaceuticals to Present at the 36th Annual Oppenheimer Healthcare Life Sciences Conference

NORWOOD, Mass., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), a clinical-stage company focused on oncology and obesity, today announced that Yuval Cohen, Ph.D.,...

CRBP : 10.02 (-1.57%)
The 3 Best Cannabis Stocks to Buy for 2026

These three cannabis stocks mix regulatory optionality, steady operators, and biotech risk as investors position for 2026 reform tailwinds.

CRBP : 10.02 (-1.57%)
MAPS : 0.3600 (-2.99%)
GTBIF : 6.7200 (-0.30%)
Corbus Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference

NORWOOD, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), a clinical-stage company focused on oncology and obesity, today announced that Yuval Cohen, Ph.D.,...

CRBP : 10.02 (-1.57%)
Corbus Pharmaceuticals Reports Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity Demonstrating Favorable Safety Profile and Emerging Evidence of Weight Loss

CRB-913 was safe and well-tolerated across all doses studied Daily neuropsychiatric assessments using CSSRS, PHQ-9, and GAD-7 were negative for all participants A placebo-adjusted mean weight loss...

CRBP : 10.02 (-1.57%)
Corbus Pharmaceuticals to Report Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity on Thursday, December 11, 2025

NORWOOD, Mass., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), a clinical stage company focused on oncology and obesity, announced the Company’s plan to release...

CRBP : 10.02 (-1.57%)

Business Summary

Corbus Pharmaceuticals Holdings, Inc. is a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company's lead product candidate, lenabasum, is a novel, synthetic...

See More

Key Turning Points

3rd Resistance Point 11.10
2nd Resistance Point 10.87
1st Resistance Point 10.45
Last Price 10.02
1st Support Level 9.80
2nd Support Level 9.57
3rd Support Level 9.15

See More

52-Week High 20.56
Fibonacci 61.8% 14.89
Fibonacci 50% 13.14
Fibonacci 38.2% 11.40
Last Price 10.02
52-Week Low 5.73

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.